Measles, mumps, and rubella
Conditions
Brief summary
Primary endpoint The primary trial endpoint is levels of measles-specific mucosal IgA immune response 3 months after EV compared with the standard MMRvaccine administration by subcutaneous/intramuscular injection as measured by ELISA methods. We hypothesize that there is no significant difference between the levels.
Detailed description
Nasal secretion and serum: Measles neutralizing antibodies measured by gold standard PRNT Measles, mumps, and rubella IgG, IgM and IgA measured by ELISA Full blood: Measles-specific CD4+ and CD8+ T-cell responses Tonsil brushings: Measles-specific CD4+ and CD8+ T-cell responses Side effects: Frequency of side effects/adverse events 30 days after vaccination will be compared
Interventions
Sponsors
Rigshospitalet
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint The primary trial endpoint is levels of measles-specific mucosal IgA immune response 3 months after EV compared with the standard MMRvaccine administration by subcutaneous/intramuscular injection as measured by ELISA methods. We hypothesize that there is no significant difference between the levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Nasal secretion and serum: Measles neutralizing antibodies measured by gold standard PRNT Measles, mumps, and rubella IgG, IgM and IgA measured by ELISA Full blood: Measles-specific CD4+ and CD8+ T-cell responses Tonsil brushings: Measles-specific CD4+ and CD8+ T-cell responses Side effects: Frequency of side effects/adverse events 30 days after vaccination will be compared | — |
Countries
Denmark
Outcome results
None listed